Send us a text

Editor-in-Chief, Robert Amdur, MD, reviews a Topic Discussion paper from the September/October issue of PRO, "Variation in Routine Use of a 60-63 Gy Intermediate Dose CTV with Primary Radiotherapy for Mucosal Squamous Cell Carcinoma of the Head and Neck." This paper summarizes major published guidelines on the use of an intermediate risk target volume and the current practice of four clinicians that specialize in head and neck radiotherapy.